STL Index for: Maddin Stuart
Pimecrolimus and Tacrolimus: The US FDA Public Health Advisory
In February of this year, the US FDA issued a public health advisory to inform healthcare providers and patients about a potential cancer risk from the topical use of pimecrolimus (Elidel©, Novartis), approved by the FDA in December 2001, and tacrolimus (Protopic©, Astellas, formerly Fujisawa), approved in December 2000.
US FDA Advisory Committee Meetings Held to Discuss Isotretinoin, Safety Issues and a New Accutane Formulation
There is no drug that has provided as much therapeutic benefit for 12 million acne patients as this retinoid has done in the past 18 years following its introduction. However, it is a retinoid and, therefore, a teratogen.
